By achieving certification for the assay, called PredictSure IBD, the Cambridge, UK-based firm can sell it for clinical use across Europe.
In adults and children with Crohn's, miR-31 was found at higher levels in gut tissue, and the cases marked by lower expression tended to have poorer outcomes.
The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
The panel is designed to measure genetic markers in whole-blood samples in order to predict which patients are likely to experience a severe, relapsing form of the disease.
In Science this week: mutations that allow the malaria parasite to evade treatment, and more.
New research suggests that some risky and protective variants in the LRRK2 gene have shared genetic effects in Crohn's disease and Parkinson's disease.
Gut microbiome researchers have identified features associated with everything from Crohn's disease to salt intake, immune activity, and hypertension.
The newly announced Microbiome Immunity Project seeks to discover links between autoimmune diseases and bacteria in and on the human body.
A team has identified disease loci for Crohn's and ulcerative colitis using fine mapping alongside high-density genotyping.
Researchers have sequenced the genome of the depth-dwelling giant squid.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.
Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.
In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.